Trial Profile
A Phase I Dose Finding Study of the Pan-DAC Inhibitor Panobinostat (LBH589) in Combination With Etoposide and Cisplatin in the First Line Treatment of Extensive-Stage Small Cell Lung Cancer - An ICORG In-House Study.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 23 Jun 2016
Price :
$35
*
At a glance
- Drugs Panobinostat (Primary) ; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 22 Jul 2010 New trial record